Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
Galectin Therapeutics Inc. (GALT)
Last galectin therapeutics inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.galectintherapeutics.com/investor-relations
Company Research
Source: GlobeNewswire
NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright MASH Investor Conference being held October 7, 2024. Dr. Jamil will be sharing the latest updates on clinical programs and pipeline advancement on October 7, 2024 at 10:00 AM ET. The webcast of the presentation can be accessed here or through the Company’s website on the Events & Presentation page of the investors section. About Galectin TherapeuticsGalectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it h
Show less
Read more
Impact Snapshot
Event Time:
GALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GALT alerts
High impacting Galectin Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GALT
News
- Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting [Yahoo! Finance]Yahoo! Finance
- Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver MeetingGlobeNewswire
- Galectin Therapeutics Inc. (NASDAQ: GALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update [Yahoo! Finance]Yahoo! Finance
GALT
Earnings
- 11/14/24 - Beat
GALT
Analyst Actions
- 11/15/24 - HC Wainwright
GALT
Sec Filings
- 11/14/24 - Form 8-K
- 11/14/24 - Form 8-K
- 11/14/24 - Form 10-Q
- GALT's page on the SEC website